Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.
Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.
复制标题
DOI：
10.1038/cgt.2014.15
复制
发表时间：
2014-05
影响因子：
6.4
通讯作者：
中科院分区：
文献类型：
--
作者：
尽管结直肠癌 (CRC) 的死亡率正在下降，但结直肠癌仍然是美国癌症相关死亡的第二大原因。尽管我们仍然缺乏克服治疗耐药性的新策略，但化疗和放疗现在在我们抗击癌症的策略中发挥着核心作用。结直肠癌治疗耐药的分子机制仍在深入研究中。在这篇综述中，我们重点介绍了上皮间质转化（EMT）与侵袭性肿瘤生物学以及包括结肠癌在内的多个器官系统的癌症干细胞（CSC）之间的联系。此外，在新辅助治疗时代，临床意义在于我们的治疗可能有可能通过 EMT 诱导更具侵袭性的癌细胞，甚至可能产生更有能力转移和进一步抵抗治疗的 CSC。这种担忧和潜在的现实凸显了进一步了解临床治疗对癌症病理学影响的迫切需要，并进一步支持了针对 CSC 进行治疗的需要。除了作为侵袭性肿瘤生物学和治疗耐药性的潜在生物标志物外，EMT 和 CSC 分子途径还可以突出新的治疗靶点，作为改善传统抗肿瘤药物反应的策略，从而转化为改善的肿瘤学结果。
Although mortality from colorectal cancer (CRC) is decreasing, colorectal cancer is still the second highest cause of cancer related deaths in America. Chemotherapy and radiation therapy now play central roles in our strategies to fight cancer, although we continue to lack novel strategies overcoming therapeutic resistance. Molecular mechanisms of therapeutic resistance in CRC continue to be under intense investigation. In this review, we highlight the recent evidence linking epithelial-to-mesenchymal transition (EMT) with aggressive tumor biology as well as with the cancer stem cells (CSC) across multiple organ systems including colon cancer. Furthermore, in the era of neo-adjuvant treatment, the clinical implications are concerning that our treatments may have the potential to induce more aggressive cancer cells through EMT, perhaps even generating CSCs more capable of metastasis and further resistant to treatment. This concern and potential reality highlights the critical need for further understanding the impact of clinical therapy on the pathobiology of cancer and further supports the need to therapeutically target the CSC. Besides serving as potential biomarkers for aggressive tumor biology and therapeutic resistance, EMT and CSC molecular pathways may highlight novel therapeutic targets as strategies for improving the response to conventional anti-neoplastic agents translating into improved oncologic outcomes.
登录
查看更多内容
影响因子：
21.3
作者：
Batlle, E;Sancho, E;de Herreros, AG
通讯作者：
de Herreros, AG
DOI：
10.1073/pnas.0703478104
发表时间：
2007-06-12
影响因子：
11.1
作者：
Dalerba, Piero;Dylla, Scott J.;Clarke, Michael F.
通讯作者：
Clarke, Michael F.
影响因子：
8.8
作者：
Fan, F.;Samuel, S.;Gaur, P.;Lu, J.;Dallas, N. A.;Xia, L.;Bose, D.;Ramachandran, V.;Ellis, L. M.
通讯作者：
Ellis, L. M.
影响因子：
3.8
作者：
Arndt GM;Dossey L;Cullen LM;Lai A;Druker R;Eisbacher M;Zhang C;Tran N;Fan H;Retzlaff K;Bittner A;Raponi M
通讯作者：
Raponi M
影响因子：
3.8
作者：
Cheng, Chun-Wen;Wang, Hsiao-Wei;Shen, Chen-Yang
通讯作者：
Shen, Chen-Yang